GSK looking to sell part of antibiotics business

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/Stas_V)
(Image: Getty/Stas_V)

Related tags: Gsk, Glaxosmithkline

GSK reportedly exploring the sale of part of its antibiotics business, as it refocuses its operations towards R&D.

Bloomberg reported​ on Friday that the UK drugmaker, GlaxoSmithKline, is in deliberations to sell a part of its portfolio of antibiotics, however, there is ‘no certainty’ that this will lead to a transaction.

The sale could reportedly bring in ‘several hundreds of million dollars,’ with the company cashing out on drug products that generate about $200m (€179m) in annual revenue.

The company recently announced plans to separate out its consumer health business from its core operations under a ‘transformation plan’, which would also include the slimming down of its vaccines business, including the cutting of 935 jobs in Belgium​.

The ‘new GSK’ that will be formed following that separation will see it focus on R&D operations, particularly on immunology, genetics and new technologies, while concurrently increasing its investments in R&D and the launch of new products.

In February, the company also proceeded with the sale of 15 of its consumer healthcare products to generic drugmaker Stada for over €300m.

Related news

Follow us

Products

View more

Webinars